18:10:56 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-08 Kvartalsrapport 2024-Q3
2024-08-23 Kvartalsrapport 2024-Q2
2024-05-14 Kvartalsrapport 2024-Q1
2024-04-29 Ordinarie utdelning OMDA 0.48 NOK
2024-04-25 Årsstämma 2024
2024-03-01 Bokslutskommuniké 2023
2023-11-10 Kvartalsrapport 2023-Q3
2023-09-26 Extra Bolagsstämma 2023
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-12 Kvartalsrapport 2023-Q1
2023-04-28 Ordinarie utdelning OMDA 0.00 NOK
2023-04-27 Årsstämma 2023
2023-02-28 Bokslutskommuniké 2022
2022-11-30 Kvartalsrapport 2022-Q3
2022-10-03 Extra Bolagsstämma 2022
2022-08-30 Kvartalsrapport 2022-Q2
2022-05-20 Ordinarie utdelning OMDA 0.00 NOK
2022-05-19 Kvartalsrapport 2022-Q1
2022-05-19 Årsstämma 2022
2022-02-25 Bokslutskommuniké 2021
2021-11-26 Kvartalsrapport 2021-Q3
2021-08-31 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-05-07 Ordinarie utdelning OMDA 0.00 NOK
2021-05-06 Årsstämma 2021
2021-02-26 Bokslutskommuniké 2020
2020-12-11 Extra Bolagsstämma 2020
2020-11-27 Kvartalsrapport 2020-Q3

Beskrivning

LandNorge
ListaEuronext Growth Oslo
SektorInformationsteknik
IndustriProgramvara
OMDA är verksamma inom teknikbranschen. Bolaget är specialiserade inom utveckling av digitala plattformar för vården. Programvaran är egenutvecklad och används huvudsakligen för analys och uppföljning av olika områden inom sjukvården. Utöver huvudverksamheten erbjuds även diverse mervärdestjänster. Verksamhet innehas på global nivå med störst närvaro inom den europeiska marknaden.
2023-11-10 07:00:00
Oslo, Norway, 10 November 2023: Today, Omda AS ("Omda"), a leading provider of
specialised software for healthcare, published its results for the third quarter
of 2023.

Omda (previously CSAM Health Group) continues its strong growth and reported
revenues of NOK 100 million for Q3-23, a 15% increase over Q3-22. Similarly, the
recurring revenue increased to NOK 79 million in Q3-23, up from 71 million for
the same period last year. The growth is founded on healthy operations,
evidenced by the EBITDA margin, which was 27% for the quarter, up from 5% in
Q1-23 and 10% in Q2-23.

Omda CEO Sverre Flatby emphasises the continued growth and solid fundamentals:
"A strong quarter for Omda. We delivered significant growth in revenue, EBITDA
and recurring revenue. The income year-to-date reached NOK 306 million, and we
are comfortably on track to reach our NOK 400 million target for the year."

Omda's growth in recurring revenue and margins originate from a proven strategy
of building long-term relationships with customers in several countries. By
constantly improving to meet the user needs, Omda secures long-term contracts
that generate a diversified revenue stream with minor customer churn.

"As we look to the end of this year and into 2024, we are optimistic, and we see
interesting opportunities - both in our existing Business Areas and when it
comes to M&A," Flatby concludes.

Highlights from the report:
o Q3-23 total income 100 MNOK vs 86 MNOK in Q3-22
o Recurring revenue grew 11% to 79 MNOK and accounted for 80% of total sales
o Reported EBITDA was 27 MNOK resulting in a 27% EBITDA margin
o Q3-23 organic growth of 11% in local currency (13% in NOK)
o Gross margin increased to 93% (92%)
o CSAM successfully rebrands to Omda


For more information, please contact:
Einar Bonnevie
Chief Financial Officer
+47 91 55 45 32
einar.bonnevie@omda.com

About Omda
Omda is the leading provider of specialised software for healthcare and
emergency services in the Nordics with a growing presence in Europe, North
America and the Pacific region. The company serves more than 500 customers in 27
countries and employs almost 300 dedicated specialists. Our highly specialised
healthcare solutions empower medical professionals and emergency responders,
enabling them to know more and work smarter. With a focus on user-centric
design, value-driven development and close working relationships with customers,
Omda delivers solutions that enhance patient safety and improve healthcare
outcomes.

For more information, visit www.omda.com
Follow us on LinkedIn
Subscribe to our newsletter: http://eepurl.com/dsoOJH